Intercept to Present at Upcoming Investor Conferences

Intercept to Present at Upcoming Investor Conferences

NEW YORK, June 6, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
(Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver and intestinal diseases, today announced management will
be participating in the following upcoming investor conferences:

  *Dr. Mark Pruzanski, Chief Executive Officer, will present at the Goldman
    Sachs 35^th Annual Global Healthcare Conference at 10:40 a.m. PT on
    Thursday, June 12, 2014 in Los Angeles
  *Dr. Pruzanski will participate in the Citi NASH Workshop on Monday, June
    23, 2014 in New York
  *Dr. Rachel McMinn, Chief Strategy Officer, will present at the JMP
    Securities Health Care Conference at 10:00 a.m. ET on Wednesday, June 25,
    2014 in New York

Information for the availability of live webcasts for these events will be
posted on the Investors page of Intercept's website at
http://ir.interceptpharma.com. Archived webcasts will be available on
Intercept's website for approximately two weeks following each event.

About Intercept

Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver and intestinal diseases utilizing its expertise in bile acid chemistry.
The company's lead product candidate, obeticholic acid (OCA), is a bile acid
analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is
being developed for a variety of chronic liver diseases including primary
biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal
hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA
has met the primary efficacy endpoint in five placebo-controlled clinical
trials, including the recently completed POISE Phase 3 clinical trial in
patients with PBC and two Phase 2 clinical trials in NASH and nonalcoholic
fatty liver disease. OCA has received orphan drug designation in both the
United States and Europe for the treatment of PBC and PSC. Intercept owns
worldwide rights to OCA outside of Japan and China, where it has out-licensed
the product candidate to Dainippon Sumitomo Pharma (DSP). For more information
about Intercept, please visit the Company's website at:
www.interceptpharma.com.

CONTACT: For more information about Intercept,
         please contact Barbara Duncan or Senthil Sundaram,
         both of Intercept Pharmaceuticals at 1-646-747-1000.
         Media inquiries: media@interceptpharma.com
         Investor inquiries: investors@interceptpharma.com

Intercept Pharmaceuticals, Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.